May 18, 2026 04:00PM
May 18, 2026 04:00PM
May 13, 2026 07:30AM
Feb 17, 2026 07:30AM
Nov 13, 2025 07:30AM
Nov 12, 2025 12:15PM
Nov 12, 2025 12:15PM Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Nov 6, 2025 08:00AM
Aug 8, 2025 04:00PM
Aug 8, 2025 04:00PM
May 14, 2025 07:30AM
May 9, 2025 07:30AM
May 9, 2025 07:30AM
May 8, 2025 10:19PM Palatin Technologies Announces Closing of Reduced Public Offering
May 8, 2025 04:39PM
May 7, 2025 08:01AM
May 7, 2025 08:00AM
May 5, 2025 07:30AM
Apr 29, 2025 07:30AM
Apr 29, 2025 07:30AM
Apr 17, 2025 07:30AM Palatin Technologies (PTN) Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Apr 17, 2025 07:30AM
Apr 10, 2025 07:30AM
Apr 10, 2025 07:30AM
Mar 31, 2025 07:36AM
Mar 31, 2025 07:30AM
Mar 28, 2025 07:30AM
Mar 28, 2025 07:30AM Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Mar 25, 2025 07:31AM
Mar 25, 2025 07:30AM
Feb 13, 2025 07:30AM
Feb 7, 2025 08:00AM
Feb 7, 2025 08:00AM
Feb 6, 2025 07:32AM
Feb 6, 2025 07:30AM Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Jan 28, 2025 07:31AM
Jan 28, 2025 07:30AM
Dec 19, 2024 07:31AM
Dec 19, 2024 07:30AM
Dec 16, 2024 07:31AM
Dec 16, 2024 07:30AM
Nov 25, 2024 07:30AM Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Nov 14, 2024 07:30AM
Nov 4, 2024 07:30AM
Oct 31, 2024 07:30AM
Oct 24, 2024 07:30AM
Oct 23, 2024 07:30AM
Oct 1, 2024 07:32AM
Oct 1, 2024 07:30AM Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Sep 9, 2024 07:31AM

322,094 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All